Furthermore, both RNA Pol I inhibitors induced an increase in CD38 expression on MM cells, thereby potentiating Daratumumab-mediated ADCC, with BMH-21 demonstrating the most pronounced effect (Fig. 8). This evidence concerns the gene CD38 and Miyoshi myopathy.